Einige Probleme der Erfassung aggressiven Verhaltens im psychologischen Labor

Mummendey HD. Einige Probleme der Erfassung aggressiven Verhaltens im psychologischen Labor. In: Hilke R, ed. Aggression: naturwissenschaftliche und kulturwissenschaftliche Perspektiven der Aggressionsforschung. Bern: Huber; 1982: 361-377

Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study : A Randomized Clinical Trial

Importance: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). Objective: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS. Design, Setting, and Participants: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5.5, and recent clinical or magnetic resonance imaging disease activity. Interventions: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1Pmodulators and a follow-up period of 30 days. Main Outcomes and Measures: The primary end point was the annualized relapse rate. The secondary end points were the changes in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, the number of combined unique active lesions per year on magnetic resonance imaging, and time to 12-week and 24-week confirmed disability accumulation. Safety and tolerability were assessed. Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status. Results: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [64.9%]), the relative rate reduction for ponesimod vs teriflunomide in the annualized relapse rate was 30.5% (0.202 vs 0.290; P <.001); the mean difference in FSIQ-RMS, -3.57 (-0.01 vs 3.56; P <.001); the relative risk reduction in combined unique active lesions per year, 56% (1.405 vs 3.164; P <.001); and the reduction in time to 12-week and 24-week confirmed disability accumulation risk estimates, 17% (10.1% vs 12.4%; P =.29) and 16% (8.1% vs 9.9; P =.37), respectively. Brain volume loss at week 108 was lower by 0.34% (-0.91% vs -1.25%; P <.001); the odds ratio for NEDA-3 achievement was 1.70 (25.0% vs 16.4%; P <.001). Incidence of treatment-emergent adverse events (502 of 565 [88.8%] vs 499 of 566 [88.2%]) and serious treatment-emergent adverse events (49 [8.7%] vs 46 [8.1%]) was similar for both groups. Treatment discontinuations because of adverse events was more common in the ponesimod group (49 of 565 [8.7%] vs 34 of 566 [6.0%]). Conclusions and Relevance: In this study, ponesimod was superior to teriflunomide on annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status, but not confirmed disability accumulation. The safety profile was in line with the previous safety observations with ponesimod and the known profile of other S1P receptor modulators

Demonstration of Feeding Vehicle-Integrated Photovoltaic-Converted Energy into the High-Voltage On-Board Network of Practical Light Commercial Vehicles for Range Extension

The setting up of a practical electrically driven light commercial demonstration vehicle with integrated photovoltaics (PV) is reported. The demonstrator vehicle is equipped with 15 modules based on the crystalline Si/amorphous Si heterojunction technology. The nominal total peak power under standard testing conditions is 2180 Wp. Specifically, the PV-converted energy is fed into the high-voltage (HV; 400 V) board-net for a utilization of the large capacity of the HV battery and thus for direct range extension. The demonstrator vehicle is equipped with irradiation, wind, temperature, magnetic, and global positioning system sensors. Irradiation and temperature as well as the energy flows from modules, maximum power point trackers (MPPTs), low-voltage buffer battery to HV battery via DC/DC, and from the HV battery to the loads during an exemplarily test drive day (May 31, 2021) are monitored. The range extension obtained at this day on our test route (51° 59′ N, 9° 31′ E) was 36 km, the corresponding CO2 savings account for ≈2.3 kg. The chain efficiency of the electronic components from the input side of the MPPTs to the HV output side of the DC/DC was 68.6%, whereas the DC/DC itself has an average efficiency of 90%. © 2021 The Authors. Solar RRL published by Wiley-VCH Gmb

The Super-Earth Opportunity - Search for Habitable Exoplanets in the 2020s

The recent discovery of a staggering diversity of planets beyond the Solar System has brought with it a greatly expanded search space for habitable worlds. The Kepler exoplanet survey has revealed that most planets in our interstellar neighborhood are larger than Earth and smaller than Neptune. Collectively termed super-Earths and mini-Neptunes, some of these planets may have the conditions to support liquid water oceans, and thus Earth-like biology, despite differing in many ways from our own planet. In addition to their quantitative abundance, super-Earths are relatively large and are thus more easily detected than true Earth twins. As a result, super-Earths represent a uniquely powerful opportunity to discover and explore a panoply of fascinating and potentially habitable planets in 2020 - 2030 and beyond.Comment: Science white paper submitted to the 2020 Astronomy and Astrophysics Decadal Surve

The Super-Earth Opportunity - Search for Habitable Exoplanets in the 2020s

The recent discovery of a staggering diversity of planets beyond the Solar System has brought with it a greatly expanded search space for habitable worlds. The Kepler exoplanet survey has revealed that most planets in our interstellar neighborhood are larger than Earth and smaller than Neptune. Collectively termed super-Earths and mini-Neptunes, some of these planets may have the conditions to support liquid water oceans, and thus Earth-like biology, despite differing in many ways from our own planet. In addition to their quantitative abundance, super-Earths are relatively large and are thus more easily detected than true Earth twins. As a result, super-Earths represent a uniquely powerful opportunity to discover and explore a panoply of fascinating and potentially habitable planets in 2020 - 2030 and beyond

Zur Rechtfertigung der Aggressionsmaschine

Es wird untersucht, inwieweit in Aggressionsmaschine eine eindeutige Klassifikation von Handlungen als "aggressiv" bzw. "nicht aggressiv" möglich ist. Ausgehend von einer Diskussion der konträren Definitionsvorschläge von Buss und WERBIK wird ein Klassifikationssystem für "aggressive" Handlungen entwickelt, aus dem konkrete Hinweise für die Gestaltung von Versuchsanordnungen in der Aggressionsmaschine deduzierbar sind. Die Anwendbarkeit des Systems auf andere Versuchsanordnungen, wie sie in der Aggressions- und Konfliktforschung üblich sind. wird am Beispiel des "prisoner's dilemma game" aufgezeigt. Obwohl das Klassifikationssystem eine Weiterführung des WERBIKschen Definitionsvorschlages darstellt, kann auf "Sprachnormierung" verzichtet werden